Close Menu

Phenotypic screening is once again popular at many large pharmaceutical companies, as the targeted drug discovery approach is being considered too limiting in certain ways, says Joanne Kotz at SciBX. "Phenotypic screens used to be the mainstay of drug development," Kotz says. Since the 1980s, advances in molecular biology and genomics have led drug companies to use targeted screening method to develop drugs.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.